|
       |
|
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Partners . . . . . . . . . . . . . . . . . . . . . .
|
Partnering is an integral component of NeuroPhage's strategy which is to maximize the commercial potential of its proprietary phage technology platform thus expediting the development of new therapies for the various neurodegenerative diseases we serve. NeuroPhage views partnerships as a direct channel to near term, mid term and long term value creation and our goal is to collaborate with leading pharmaceutical and biotechnology companies by leveraging our robust platform technology. Companies interested in exploring partnering opportunities with NeuroPhage should contact: bd@neurophage.com Current Partners:Michael J. Fox FoundationThe Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.
|
